MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Table 4

Selected patient and tumor characteristics and response to CCRT in comparison to excision repair genes and MMP9 status.

					ERCC1	ERCC1	ERCC1 C8092A/	ERCC2-	ERCC2-	XRCC1-	MMP9
n	Primary site	Gender	Age	Response	(IHC)	(mRNA)	CD3EAP Q504K#	312#	751#	399#	(mRNA)
(1)	Oral Cavity	W	69	PR	N	H	A/A	Asn/Asp	Gln/Lys	Arg/Arg	H
(2)	Oral Cavity	M	66	PR	P	H	C/C	Asp/Asp	Lys/Lys	Arg/Arg	H
(3)	Oral Cavity	M	59	PR	P	L	C/C	Asp/Asp	Lys/Lys	Arg/Arg	H
(4)	Oral Cavity	M	82	CR	P	H	C/C	Asp/Asp	Lys/Lys	Gln/Arg	H
(5)	Oral Cavity	M	61	NE	P	L	A/C	Asp/Asp^⋀	Gln/Lys	Gln/Arg	L
(6)	Oral Cavity	M	69	PD	P	L	A/C*	Asn/Asn*	Gln/Gln*	Gln/Gln*	L
(7)	Oral Cavity	W	41	PD	P	L	A/C*	Asn/Asp*	Gln/Lys*	Gln/Arg*	L
(8)	Oral Cavity	W	60	CR	P	H	C/C	Asp/Asp	Lys/Lys	Gln/Arg	H
(9)	Oral Cavity	M	44	CR	P	H	C/C	Asn/Asn	Gln/Gln	Arg/Arg	H
(10)	Oral Cavity	M	60	ED	P	L	C/C	undet.	undet.	undet.	L
(11)	Oral Cavity	W	59	PD	P	L	A/C	Asn/Asp	Gln/Lys	Arg/Arg	H
(12)	Oral Cavity	W	55	CR	Undet.	Undet.	A/C	Asp/Asp	Lys/Lys	Gln/Arg	Undet.
(13)	Oropharynx	M	57	CR	P	H	C/C	undet.	undet.	undet.	H
(14)	Oropharynx	W	36	CR	P	L	C/C	Asn/Asp	Gln/Gln	Gln/Arg	H
(15)	Oropharynx	M	59	CR	P	L	A/C	Asn/Asp	Gln/Lys	Gln/Arg	L
(16)	Oropharynx	W	55	CR	N	H	A/C	Asn/Asp	Gln/Lys	Arg/Arg	H
(17)	Oropharynx	M	69	PR	P	Undet.	A/C	Asn/Asn	Gln/Lys	Gln/Arg	Undet.
(18)	Oropharynx	M	46	CR	N	L	C/C	Asn/Asp	Gln/Lys	Arg/Arg	L
(19)	Oropharynx	M	73	PD	P	L	C/C	Asp/Asp^⋀	Gln/Lys	Gln/Gln	L
(20)	Oropharynx	M	67	SD	P	H	A/A	Asn/Asn	Gln/Gln	Gln/Arg	L
(21)	Hypopharynx	M	46	CR	P	H	A/C	Asn/Asp	Gln/Lys	Gln/Arg	H
(22)	Hypopharynx	W	64	PR	N	H	C/C	Asp/Asp	Lys/Lys	Arg/Arg	L
(23)	Hypopharynx	M	56	ED	P	L	A/C	Asn/Asp^⋀	Lys/Lys	Gln/Arg	L
(24)	Hypopharynx	W	56	PR	P	L	C/C*	Asn/Asp*	Gln/Lys*	Gln/Arg*	H
(25)	Larynx	M	55	CR	N	H	A/C	Asn/Asp	Gln/Lys	Gln/Arg	H
(26)	Larynx	M	68	PR	N	L	A/A	Asp/Asp	Lys/Lys	Arg/Arg	L
(27)	Larynx	M	60	ED	—	Undet.	—	—	—	—	Undet.
(28)	Larynx	M	42	PR	P	N	C/C	Asn/Asn	Gln/Lys	Gln/Gln	H
(29)	Larynx	M	76	CR	P	H	A/C	Asn/Asp	Gln/Gln	Gln/Arg	L
(30)	Larynx	M	74	ED	P	N	C/C	Asn/Asp	Gln/Lys	Arg/Arg	L
(31)	Larynx	W	46	SD	P	N	A/C	Asn/Asp	Gln/Lys	Gln/Arg	L
(32)	Larynx	M	74	ED	N	H	A/A^⋀	Asn/Asp	Lys/Lys	Gln/Arg	L
(33)	Larynx	M	67	PD	N	H	C/C	Asp/Asp	Lys/Lys	Arg/Arg	L
(34)	Larynx	M	54	CR	P	N	C/C	Asp/Asp	Lys/Lys	Arg/Arg	L
(35)	Larynx	M	54	PR	P	Undet.	A/C	Asn/Asp	Gln/Lys	Gln/Arg	Undet.
(36)	Paranasal Sinuses	M	65	SD	P	H	C/C	Asp/Asp	Gln/Lys	Gln/Arg	H
(37)	Major Salivary Glands	M	74	PR	P	H	C/C	Asp/Asp	Gln/Lys	Gln/Arg	H

n = sample order number; M = man; W = woman; H = high; L = low; P = positive; N = negative; # = genotypes from tumor tissue or from matched peripheral blood and tumor tissue samples, unless otherwise specified; ⋀ = mismatched tumor/peripheral blood genotypes (tumor data are shown); * = peripheral blood data only; Undet. = undetermined by real time PCR.